by Mark Curtis | Apr 28, 2016
Welcome to your Update from the Clinic for the month of March. Undoubtedly the big news in March came from Vericel, which saw its stock double after reporting positive topline results from its Phase 2b study in heart failure. There were also some first dosings and...
by Mark Curtis | Oct 20, 2015
. Welcome to your Cell Therapy Deal Review for the month of September. Aduro Biotech went the way of Juno and Kite and bought an antibody discovery platform. Intrexon and ZIOPHARM entered into an agreement to develop a novel Treg-based immunotherapy for GvHD. Kite...
by Mark Curtis | Aug 18, 2015
. Welcome to your Cell Therapy Deal Review for the month of July. Here at Signals we’ve decided to change the name of this monthly column, to pay consideration to the fact the majority of the technologies discussed here are cell-based. Moving forward, I will continue...
by Mark Curtis | Apr 28, 2015
. After several years of intense systematic research, and toiling with a differentiation protocol, Dr. Doug Melton, and his lab at Harvard University, finally decoded the sequence of genes that needs to be activated to yield mature, insulin-producing beta cells in...
Comments